Literature DB >> 8098733

Resolution of cutaneous leishmaniasis: interleukin 12 initiates a protective T helper type 1 immune response.

J P Sypek1, C L Chung, S E Mayor, J M Subramanyam, S J Goldman, D S Sieburth, S F Wolf, R G Schaub.   

Abstract

Resistance to Leishmania major in mice is associated with the appearance of distinct T helper type 1 (Th1) and Th2 subsets. T cells from lymph nodes draining cutaneous lesions of resistant mice are primarily interferon gamma (IFN-gamma)-producing Th1 cells. In contrast, T cells from susceptible mice are principally Th2 cells that generate interleukin 4 (IL-4). Although existing evidence is supportive of a role for IFN-gamma in the generation of Th1 cells, additional factors may be required for a protective response to be maintained. A potential candidate is IL-12, a heterodimeric cytokine produced by monocytes and B cells that has multiple effects on T and natural killer cell function, including inducing IFN-gamma production. Using an experimental leishmanial model we have observed that daily intraperitoneal administration at the time of parasite challenge of either 0.33 micrograms IL-12 (a consecutive 5 d/wk for 5 wk) or 1.0 micrograms IL-12 per mouse (only a consecutive 5 d) caused a > 75% reduction in parasite burden at the site of infection, in highly susceptible BALB/c mice. Delay of treatment by 1 wk had less of a protective effect. Concomitant with these protective effects was an increase in IFN-gamma and a decrease in IL-4 production, as measured by enzyme-linked immunosorbent assay of supernatants generated from popliteal lymph node cells stimulated with leishmanial antigen in vitro. The reduction in parasite numbers induced by IL-12 therapy was still apparent at 10 wk postinfection. In addition, we observed that the administration of a rabbit anti-recombinant murine IL-12 polyclonal antibody (200 micrograms i.p. every other day for 25 d) at the time of infection to resistant C57Bl/6 mice exacerbated disease. These effects were accompanied by a shift in IFN-gamma production in vitro by antigen-stimulated lymph node cells indicative of a Th2-like response. These findings suggest that IL-12 has an important role in initiating a Th1 response and protective immunity.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8098733      PMCID: PMC2191036          DOI: 10.1084/jem.177.6.1797

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  20 in total

1.  Monoclonal antibodies to murine gamma-interferon which differentially modulate macrophage activation and antiviral activity.

Authors:  R D Schreiber; L J Hicks; A Celada; N A Buchmeier; P W Gray
Journal:  J Immunol       Date:  1985-03       Impact factor: 5.422

Review 2.  Use of staphylococcal protein A as an immunological reagent.

Authors:  J W Goding
Journal:  J Immunol Methods       Date:  1978       Impact factor: 2.303

3.  Epitopes on CD45R [T200] molecules define differentiation antigens on murine B and T lymphocytes.

Authors:  M L Birkeland; J Metlay; V M Sanders; R Fernandez-Botran; E S Vitetta; R M Steinman; E Puré
Journal:  J Mol Cell Immunol       Date:  1988

4.  Production of a monoclonal antibody to and molecular characterization of B-cell stimulatory factor-1.

Authors:  J Ohara; W E Paul
Journal:  Nature       Date:  1985 May 23-29       Impact factor: 49.962

5.  Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins.

Authors:  T R Mosmann; H Cherwinski; M W Bond; M A Giedlin; R L Coffman
Journal:  J Immunol       Date:  1986-04-01       Impact factor: 5.422

6.  Administration of monoclonal anti-IFN-gamma antibodies in vivo abrogates natural resistance of C3H/HeN mice to infection with Leishmania major.

Authors:  M Belosevic; D S Finbloom; P H Van Der Meide; M V Slayter; C A Nacy
Journal:  J Immunol       Date:  1989-07-01       Impact factor: 5.422

7.  Cell contact-mediated macrophage activation for antileishmanial defense. I. Lymphocyte effector mechanism that is contact dependent and noncytotoxic.

Authors:  C B Panosian; J P Sypek; D J Wyler
Journal:  J Immunol       Date:  1984-12       Impact factor: 5.422

8.  Immunoregulation of cutaneous leishmaniasis. T cell lines that transfer protective immunity or exacerbation belong to different T helper subsets and respond to distinct parasite antigens.

Authors:  P Scott; P Natovitz; R L Coffman; E Pearce; A Sher
Journal:  J Exp Med       Date:  1988-11-01       Impact factor: 14.307

9.  Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes.

Authors:  M Kobayashi; L Fitz; M Ryan; R M Hewick; S C Clark; S Chan; R Loudon; F Sherman; B Perussia; G Trinchieri
Journal:  J Exp Med       Date:  1989-09-01       Impact factor: 14.307

10.  Cure of murine leishmaniasis with anti-interleukin 4 monoclonal antibody. Evidence for a T cell-dependent, interferon gamma-independent mechanism.

Authors:  M D Sadick; F P Heinzel; B J Holaday; R T Pu; R S Dawkins; R M Locksley
Journal:  J Exp Med       Date:  1990-01-01       Impact factor: 14.307

View more
  194 in total

1.  Activation of mononuclear cells by interleukin-12: an in vivo study in chimpanzees.

Authors:  F N Lauw; A A te Velde; P E Dekkers; P Speelman; J M Aerts; C E Hack; S J van Deventer; T van der Poll
Journal:  J Clin Immunol       Date:  1999-07       Impact factor: 8.317

2.  Virulent or avirulent (dhfr-ts-) Leishmania major elicit predominantly a type-1 cytokine response by human cells in vitro.

Authors:  C Brodskyn; S M Beverley; R G Titus
Journal:  Clin Exp Immunol       Date:  2000-02       Impact factor: 4.330

3.  Coadministration of interleukin 12 expression vector with antigen 2 cDNA enhances induction of protective immunity against Coccidioides immitis.

Authors:  C Jiang; D M Magee; R A Cox
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

4.  Evolution of lesion formation, parasitic load, immune response, and reservoir potential in C57BL/6 mice following high- and low-dose challenge with Leishmania major.

Authors:  R Lira; M Doherty; G Modi; D Sacks
Journal:  Infect Immun       Date:  2000-09       Impact factor: 3.441

Review 5.  Clinical and experimental advances in treatment of visceral leishmaniasis.

Authors:  H W Murray
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

6.  Interleukin-12 is capable of generating an antigen-specific Th1-type response in the presence of an ongoing infection-driven Th2-type response.

Authors:  L R Schopf; J L Bliss; L M Lavigne; C L Chung; S F Wolf; J P Sypek
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

7.  Systemic cytokine response in humans with chiclero's ulcers.

Authors:  C M Lezama-Davila; A P Isaac-Marquez
Journal:  Parasitol Res       Date:  2006-04-22       Impact factor: 2.289

Review 8.  Pro- and anti-inflammatory cytokines in cutaneous leishmaniasis: a review.

Authors:  Nahid Maspi; Amir Abdoli; Fathemeh Ghaffarifar
Journal:  Pathog Glob Health       Date:  2016-09-23       Impact factor: 2.894

9.  UNC93B1 and nucleic acid-sensing Toll-like receptors mediate host resistance to infection with Leishmania major.

Authors:  Bruno Luiz Fonseca Schamber-Reis; Patricia M Petritus; Braulia C Caetano; Espiridion R Martinez; Kendi Okuda; Douglas Golenbock; Phillip Scott; Ricardo T Gazzinelli
Journal:  J Biol Chem       Date:  2013-01-16       Impact factor: 5.157

10.  Depletion of interleukin-4 in BALB/c mice with established Leishmania major infections increases the efficacy of antimony therapy and promotes Th1-like responses.

Authors:  G S Nabors; J P Farrell
Journal:  Infect Immun       Date:  1994-12       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.